Clinical Research Directory

Inclusion Criteria: * Female patients aged ≥ 18 but ≤ 75 years * Histologically confirmed to be HER2-positive invasive breast cancer * Treatment-naive patients with stage II-III * Eastern Cooperative Oncology Group (ECOG) score 0-1 * Good level of organ function Exclusion Criteria: * Previously received any anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.) * Received any other anti-tumor therapy at the same time * Bilateral breast cancer, inflammatory breast cancer or occult breast cancer * Stage IV breast cancer * With a history of any malignancies in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer * Inability to swallow, chronic diarrhea, intestinal obstruction, and a variety of factors affecting drug administration and absorption * Participated in other drug clinical trials within 4 weeks before enrollment * History of allergies to the drug components of this protocol * Clinically significant pulmonary diseases * Clinically significant cardiovascular diseases * History of immunodeficiency * Active hepatitis and liver cirrhosis